newsfilter
← Latest News
GlobeNewswire·

Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

Announced intent to separate biopharma operations from substantial royalty assets by YE 2026Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis on track for Nov./Dec.